"Achieving statistical significance on a histology endpoint in compensated cirrhosis due to NASH has proven to be an extremely high bar in clinical trials," said Intercept's chief medical officer ...

The results of our VK2735 oral tablet program for obesity, the histology results from our VK2809 program for the treatment of NASH and fibrosis and the initial proof-of-concept data from our ...

NASH, part of the spectrum of NAFLD ... −16.1 AST in −40.1 vs. −29.5 no report in histology Liu Zhi-ye [34] Effective rate 86/96 vs. 38/54 no report in histology All comparisons are ...

Nonalcoholic fatty liver disease (NAFLD) and its more severe form NASH are common liver diseases ... induced inflammation and improving cellular histology. Successful treatment will need to ...

The last time I wrote about Akero Therapeutics (NASDAQ:AKRO) it was with respect to a Seeking Alpha article entitled as "Akero: Phase 2b NASH Data ... There is a histology biomarker study that ...

In the second quarter of 2024, Viking announced the initial histology results from the VOYAGE ... confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Non-alcoholic steatohepatitis-Clinical Research Network-Histologic Scoring System was used to assess histology. The radiologist and pathologist were blinded to clinical, pathological and imaging data, ...

Accordingly, lean patients showed a significant lower prevalence of NASH (54.1% vs 71.2% in lean vs non-lean patients, respectively, p<0.001). Nonetheless, half of the lean patients displayed a ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...